ALKERMES PLC (ALKS:NASDAQ)
$44.29 1.84 (4.3345%)
Analysed ALKERMES PLC (ALKS:NASDAQ) News Sources
Sector Update: Healthcare Stocks Gain in Afternoon Trading
12-05-2026
yahoo.com
Sector Update: Healthcare Stocks Advance Late Afternoon
12-05-2026
yahoo.com
Alkermes' (NASDAQ:ALKS) Soft Earnings Are Actually Better Than They Appear
13-05-2026
yahoo.com
Alkermes Showcases Data From Psychiatry Portfolio and Sleep Research into Real World Patient Experience at Spring 2026 Scientific Conferences
21-05-2026
yahoo.com
Alkermes to Showcase Leadership in Psychiatry and Orexin Biology With New Data at the American Society of Clinical Psychopharmacology Annual Meeting
26-05-2026
yahoo.com
Alkermes to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
03-06-2026
yahoo.com
Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at SLEEP 2026, Highlighting Breadth of Sleep Medicine Research
04-06-2026
yahoo.com
Alkermes (ALKS) Up 21.1% Since Last Earnings Report: Can It Continue?
04-06-2026
yahoo.com
Why Is Revolution Medicines (RVMD) Up 9.3% Since Last Earnings Report?
05-06-2026
yahoo.com
Should Alkermes’ Stronger Q1 2026 Results and Sleep-Medicine Advances Prompt Action From ALKS Investors?
08-06-2026
yahoo.com
What is the current price of ALKERMES PLC (ALKS:NASDAQ)?
The current price of ALKERMES PLC (ALKS:NASDAQ) is $44.29.
ALKERMES PLC (ALKS:NASDAQ) absolute price change since previous trading day?
The absolute price change of ALKERMES PLC (ALKS:NASDAQ) since the previous trading day is $1.84.
ALKERMES PLC (ALKS:NASDAQ) percentage price change since previous trading day?
The percentage price change of ALKERMES PLC (ALKS:NASDAQ) since the previous trading day is 4.3345%.
What is the most recent average sentiment score for ALKERMES PLC (ALKS:NASDAQ)?
The most recent average sentiment score for ALKERMES PLC (ALKS:NASDAQ) is 80 out of 100.
What is the most recent average sentiment for ALKERMES PLC (ALKS:NASDAQ)?
The most recent sentiment for ALKERMES PLC (ALKS:NASDAQ) is .
SEC-8K** Filing Available For ALKERMES PLC (ALKS:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.